Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology
dc.contributor.author | Abelson, James L. | en_US |
dc.contributor.author | Nesse, Randolph M. | en_US |
dc.contributor.author | Vinik, Aaron I. | en_US |
dc.date.accessioned | 2006-04-10T18:00:18Z | |
dc.date.available | 2006-04-10T18:00:18Z | |
dc.date.issued | 1994-07-15 | en_US |
dc.identifier.citation | Abelson, James L., Nesse, Randolph M., Vinik, Aaron I. (1994/07/15)."Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology." Biological Psychiatry 36(2): 84-96. <http://hdl.handle.net/2027.42/31438> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T4S-4859MF7-7N/2/db13d82067ad01e906be65cb735f0450 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31438 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7524696&dopt=citation | en_US |
dc.description.abstract | Cholecystokinin (CCK) has well-documented anxiogenic effects in animals and normal people, and panicogenic effects in patients with panic disorder, but little is known about its neuroendocrine profile. We examined neuroendocrine responses to intravenous infusions of pentagastrin, a selective CCK-B receptor agonist, in 10 patients with panic disorder and 10 normal control subjects. Pentagastrin potently activated the hypothalamic-pituitary-adrenal (HPA) axis, but did not release growth hormone or any of several vasoactive peptides (neurokinin A, substance P, vasoactive intestinal peptide). The HPA axis response was unrelated to increases in symptoms. Panic patients did not differ from controls in neuroendocrine responses to the CCK agonist. Differential sensitivity to novelty stress accounted for the only patient-control differences in neuroendocrine profiles. The data suggest that CCK may help modulate normal HPA axis activity, but its anxiogenic effects are unrelated to its stimulatory effects on the HPA axis. Pentagastrin provides a safe and readily available probe for further study of CCK receptor systems in humans. | en_US |
dc.format.extent | 2032692 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From the University of Michigan, Department of Psychiatry, Anxiety Disorders Program, Ann Arbor, MI, U.S.A. | en_US |
dc.contributor.affiliationum | From the University of Michigan, Department of Psychiatry, Anxiety Disorders Program, Ann Arbor, MI, U.S.A. | en_US |
dc.contributor.affiliationother | Eastern Virginia Medical School, Diabetes Research Institute, Norfolk, VA, U.S.A. | en_US |
dc.identifier.pmid | 7524696 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31438/1/0000356.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0006-3223(94)91188-6 | en_US |
dc.identifier.source | Biological Psychiatry | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.